Aura Biosciences, Inc. (AURA)
| Market Cap | 803.71M +89.5% |
| Revenue (ttm) | n/a |
| Net Income | -131.01M |
| EPS | -1.77 |
| Shares Out | 103.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 901,979 |
| Open | 7.77 |
| Previous Close | 8.04 |
| Day's Range | 7.07 - 7.77 |
| 52-Week Range | 4.73 - 9.54 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 16.60 (+114.19%) |
| Earnings Date | Aug 11, 2026 |
About AURA
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for AURA stock is "Strong Buy." The 12-month stock price target is $16.6, which is an increase of 114.19% from the latest price.
News
Aura Biosciences price target lowered to $18 from $24 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Aura Biosciences (AURA) to $18 from $24 and keeps a Buy rating on the shares. Aura is scaling back investment in its…
Aura Biosciences Registration statement: Registration filing
Aura Biosciences filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Aura Biosciences Earnings release: Q2 2026
Aura Biosciences released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Aura Biosciences Quarterly report: Q2 2026
Aura Biosciences has published its Q2 2026 quarterly earnings report on August 11, 2026.
Aura Biosciences Slides: Corporate presentation
Aura Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Aura Biosciences Transcript: EGM 2026
Shareholders approved increasing authorized common stock to 500 million and an amendment to the 2021 Stock Option and Incentive Plan. No questions were raised, and all proposals passed by majority vote.
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ funct...
Aura Biosciences Proxy statement: Proxy filing
Aura Biosciences filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Aura Biosciences Proxy statement: Proxy filing
Aura Biosciences filed a proxy statement on June 17, 2026, providing details for shareholder voting and corporate governance matters.
Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce com...
Aura Biosciences Transcript: AGM 2026
The meeting confirmed a quorum and approved the election of two directors and the ratification of the audit firm for 2026. No questions were raised by stockholders, and all proposals passed by the required majority.
Aura Biosciences completes enrollment in belzupacap sarotalocan trial
Aura Biosciences (AURA) announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan as a frontline treatment for patients with early choroidal melanoma...
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE...
Aura Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Bel-sar shows strong efficacy and safety in early choroidal melanoma, with phase III data expected in 2027. The company is well-financed to support ongoing trials and pipeline expansion into choroidal metastases and ocular surface cancers.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designe...
Aura Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Bel-sar is advancing as a novel therapy for ocular cancers, aiming to shift treatment paradigms by enabling early intervention and vision preservation. Key clinical trials are underway in ocular oncology and NMIBC, with significant data readouts expected through 2027.
Aura Biosciences price target lowered to $17 from $26 at Leerink
Leerink lowered the firm’s price target on Aura Biosciences (AURA) to $17 from $26 and keeps an Outperform rating on the shares.
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ functi...
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Streng...
Aura Biosciences Earnings release: Q1 2026
Aura Biosciences released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Aura Biosciences Quarterly report: Q1 2026
Aura Biosciences has published its Q1 2026 quarterly earnings report on May 11, 2026.
Aura Biosciences Slides: Corporate presentation
Aura Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve org...
Aura Biosciences Slides: Corporate presentation
Aura Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Aura Biosciences $260M Spot Secondary priced at $6.00
The deal size is 39.6M shares of its common stock and in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3.8M shares…